Genscript Biotech (HKG:1548) said it expects $505.8 million to $585.6 million in loss for 2025, compared with a profit of $2.9 billion in 2024, according to a Hong Kong bourse filing Tuesday.
Shares of the life sciences firm fell over 1% in morning trade Wednesday.
The firm attributed the reversal of profit to a high base effect in 2024 which included a one-time unrealized gain of around $3.2 billion.
Genscript also expects to record $256.1 million to $298.8 million in license revenue for the year, compared to $2.4 million in 2024.
The company's financial results are due by the end of March.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.